Glenmark – Recall of potassium chloride extended-release capsules

- On June 24, 2024, Glenmark announced a consumer level recall of 114 lots of potassium chloride extended-release capsules because of failed dissolution.
- Potassium chloride extended-release capsules were distributed nationwide.
    - Lot numbers and expiration dates for the recalled products may be found in the recall notification.
- Potassium chloride extended-release capsules are used for the treatment of patients with low potassium (hypokalemia).
- The failed dissolution of potassium chloride extended-release capsules may cause high potassium levels, also known as hyperkalemia, which can result in irregular heart beat that can lead to cardiac arrest. For patients who require chronic use of potassium chloride extended-release oral capsules, especially in those patients with underlying comorbidities or conditions that cause altered excretory mechanisms for potassium such as hypertension, heart failure, or renal dysfunction, there is a reasonable probability of developing hyperkalemia that may lead to a range of severity of adverse events from being asymptomatic to more severe potential life threatening adverse events of hyperkalemia such as cardiac arrythmias, severe muscle weakness, and death.
- To date, Glenmark has not received any reports of adverse events related to this recall.
- Anyone with the affected lots on hand should stop distribution and return product. Patients should contact their healthcare provider with any medical related questions.
- Contact Inmar Rx Solutions by phone at **1-877-883-9273** for questions regarding this recall.